Orgenesis, a global biotech company focused on cell and gene therapies (CGTs), and Cure Therapeutics, a developer of immuno-oncology and cell and gene therapies to target cancer and infectious diseases, signed a joint venture agreement. The JV aims to advance the development, regulatory and commercialization of point of care production for both organizations’ cell and gene therapies and immunotherapies. The companies will collaborate on developing and commercializing Cure Therapeutics’ p...